Galderma R&D
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Galderma R&D sits in the top decile of US sponsors by registered trial count (#186 of 15,742 sponsors by registered trial count).
Galderma R&D: 158 sponsored US clinical trials, 7 recruiting.
Galderma R&D sponsors 158 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 142 completed. 90 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 7 trials.
Top-decile sponsor footprint
Galderma R&D ranks in the top decile of sponsors by registered trial count (#186 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
142 of 146 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (97.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
158 total, page 1 of 4
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
NCT07047690
A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging
NCT07399028
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
NCT07074977
A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin
NCT07398989
A Clinical Study to Assess Histological Changes From Treatment of Poly L-lactic Acid Biostimulator on Women at Various Menopausal Stages
NCT07342400
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
NCT06988618
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
NCT06988605
Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies
NCT06351358
Study to Evaluate the Safety and Effectiveness of GP0116
NCT05987163
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
NCT04204616
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
NCT07566286
Main Study: A Study to Evaluate the Effectiveness and Safety of GAL1906 for Correction of Wrinkles in the décolletage Area Sub-study: A Follow-up Study to Evaluate the Analysis of Mammograms Following Treatment for Correction of Wrinkles in Décolletage Area in the Investigational Study 43USRV1906
NCT04717934
A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients
NCT06357221
A Comparative Analysis of Two Hyaluronic Acid Fillers for Nasolabial Fold Correction
NCT06351293
A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction
NCT06161246
A Clinical Study to Assess the Efficacy and Safety of a Healing Ointment on Diaper Rash
NCT06015217
A Study to Evaluate the Effects for Midface Improvement When Pairing a Biostimulator with a Skincare Regimen
NCT05963204
Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile
NCT05777759
Effectiveness and Safety of Restylane Contour in the Treatment of Temple Hollowing
NCT05691972
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
NCT05148000
Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler
NCT05620043
An Open-label Study of Poly-l-lactic Acid for Correction of Wrinkles in the décolletage Area
NCT05538728
Healing Ointment Usage Post-surgical Procedure
NCT05686928
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
NCT05405985
Sculptra Chart Review
NCT05463978
Comparative Ultrasound Analysis of Two Hyaluronic Acid Dermal Fillers
NCT05622851
Safety and Effectiveness of Restylane® Kysse for Lip Augmentation in Chinese Subjects
NCT05342753
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
NCT05146999
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
NCT05075408
A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
NCT05052983
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
NCT05089708
A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis
NCT04562116
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
NCT04921345
Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
NCT04856904
Restylane Defyne in a Stepwise Treatment Approach
NCT04520997
Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
NCT04501666
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
NCT04501679
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
NCT04451330
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
NCT04269395
A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
NCT04365387
Treatment of Moderate to Severe Lateral Canthal Lines
NCT04249687
Treatment of Moderate to Severe Glabellar Lines
NCT04249583
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
NCT04247074
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
NCT04225260
Extension Study for 43USSA1705
NCT04225273
Safety and Effectiveness of Sculptra Aesthetic for Correction of Cheek Wrinkles
NCT04124692
Open Label Extension for 43USSA1812
NCT04595331
Restylane-L for Correction of Infraorbital Hollows
NCT04154930
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
NCT04085367
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 24 |
| Phase 3 | 41 |
| Phase 4 | 49 |
Therapeutic Areas
Where Galderma R&D enrollment is open (later-stage tilt)
7 recruiting of 158 indexed (4% open); 142 completed (90%).
Phase mix: 90 late (III/IV) vs 28 early (I/II) (later-stage heavy).
Top condition: Acne Vulgaris (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Galderma R&D: open-pipeline peers nationwide
Peers matched on 158 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Galderma R&D sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 158 trials (± recruiting share)
- Pfizer's Upjohn has merged with Mylan to form Viatris · 158 trials · 0% recruiting
- Ann & Robert H Lurie Children's Hospital of Chicago · 159 trials · 19% recruiting
- University of South Carolina · 157 trials · 19% recruiting
- Alexion Pharmaceuticals · 162 trials · 10% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 4% recruiting · 45 trials
- Craig L Slingluff, Jr · 4% recruiting · 23 trials
- Esperion Therapeutics · 4% recruiting · 23 trials
- Tonix Pharmaceuticals · 4% recruiting · 23 trials
Related
What to do with this Galderma R&D page
158 registered trials is a research-attention snapshot, not an endorsement of Galderma R&D or any single study.
- 7 of Galderma R&D's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acne Vulgaris is the condition Galderma R&D studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Galderma R&D pipeline card: 158 registered trials from official public datasets.Report a data error.